291 related articles for article (PubMed ID: 35148283)
21. A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma.
Wang D; Zhang L; Zhang Y; Zhang Y; Xu S
Medicine (Baltimore); 2022 Jul; 101(28):e29546. PubMed ID: 35839000
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma.
Liao X; Yang C; Huang R; Han C; Yu T; Huang K; Liu X; Yu L; Zhu G; Su H; Wang X; Qin W; Deng J; Zeng X; Ye X; Peng T
Cell Physiol Biochem; 2018; 48(5):1854-1869. PubMed ID: 30092592
[TBL] [Abstract][Full Text] [Related]
23. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.
Xu BH; Jiang JH; Luo T; Jiang ZJ; Liu XY; Li LQ
Medicine (Baltimore); 2021 Jul; 100(30):e26762. PubMed ID: 34397721
[TBL] [Abstract][Full Text] [Related]
24. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
Lin X; Yang S
Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
[TBL] [Abstract][Full Text] [Related]
25. Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma.
Xia QD; Zhang Y; Li LS; Lu JL; Xun Y; Sun JX; Xu JZ; Liu CQ; Lu YC; He D; Wang SG
Dis Markers; 2022; 2022():8131007. PubMed ID: 35371341
[TBL] [Abstract][Full Text] [Related]
26. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.
Yang X; Mei M; Yang J; Guo J; Du F; Liu S
Aging (Albany NY); 2022 May; 14(9):4069-4084. PubMed ID: 35550563
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
[TBL] [Abstract][Full Text] [Related]
28. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
[TBL] [Abstract][Full Text] [Related]
29. A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma.
Zeng H; Liu C; Zhou X; Liu L
Comb Chem High Throughput Screen; 2022; 25(5):906-918. PubMed ID: 33653241
[TBL] [Abstract][Full Text] [Related]
30. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
31. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
Front Immunol; 2022; 13():929089. PubMed ID: 35874689
[TBL] [Abstract][Full Text] [Related]
32. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
33. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
34. EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
Cao D; Liu H; Bai L; Tang H
Dig Dis; 2023; 41(2):282-295. PubMed ID: 35636408
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.
Wu G; Yang Y; Ye R; Yue H; Zhang H; Huang T; Liu M; Zheng Y; Wang Y; Zhou Y; Guo Q
BMC Cancer; 2022 Oct; 22(1):1036. PubMed ID: 36195857
[TBL] [Abstract][Full Text] [Related]
36. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
[TBL] [Abstract][Full Text] [Related]
37. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
38. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
[TBL] [Abstract][Full Text] [Related]
39. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients.
Jiang H; Zhao L; Chen Y; Sun L
J Clin Lab Anal; 2020 Sep; 34(9):e23377. PubMed ID: 32474975
[TBL] [Abstract][Full Text] [Related]
40. 15-lncRNA-Based Classifier-Clinicopathologic Nomogram Improves the Prediction of Recurrence in Patients with Hepatocellular Carcinoma.
Zhang Q; Ning G; Jiang H; Huang Y; Piao J; Chen Z; Tan X; Zhang J; Liu G
Dis Markers; 2020; 2020():9180732. PubMed ID: 33520012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
